Melanie Everitt
Concepts (313)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 60 | 2025 | 714 | 9.590 |
Why?
| | Graft Rejection | 25 | 2025 | 545 | 4.200 |
Why?
| | Heart Defects, Congenital | 14 | 2023 | 880 | 2.230 |
Why?
| | Cardiomyopathies | 11 | 2024 | 333 | 2.130 |
Why?
| | Waiting Lists | 12 | 2024 | 245 | 1.460 |
Why?
| | Cardiomyopathy, Dilated | 8 | 2024 | 338 | 1.360 |
Why?
| | Registries | 17 | 2024 | 2205 | 1.320 |
Why?
| | Fontan Procedure | 5 | 2023 | 182 | 1.000 |
Why?
| | Antibodies | 8 | 2022 | 399 | 0.970 |
Why?
| | Heart Diseases | 6 | 2019 | 337 | 0.960 |
Why?
| | Heart Failure | 14 | 2024 | 2096 | 0.940 |
Why?
| | Survival Rate | 19 | 2024 | 1979 | 0.910 |
Why?
| | Child | 56 | 2025 | 22390 | 0.880 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 347 | 0.880 |
Why?
| | Heart-Assist Devices | 9 | 2024 | 561 | 0.860 |
Why?
| | Postoperative Complications | 12 | 2025 | 2831 | 0.820 |
Why?
| | Donor Selection | 3 | 2020 | 77 | 0.820 |
Why?
| | Graft Survival | 9 | 2025 | 502 | 0.810 |
Why?
| | Ventricular Dysfunction | 2 | 2013 | 16 | 0.770 |
Why?
| | Child, Preschool | 36 | 2025 | 11511 | 0.760 |
Why?
| | Tissue Donors | 5 | 2020 | 406 | 0.730 |
Why?
| | Heterotaxy Syndrome | 1 | 2021 | 14 | 0.700 |
Why?
| | Retrospective Studies | 34 | 2025 | 16447 | 0.680 |
Why?
| | Neurodevelopmental Disorders | 2 | 2024 | 213 | 0.670 |
Why?
| | Marfan Syndrome | 2 | 2011 | 43 | 0.650 |
Why?
| | Follow-Up Studies | 19 | 2024 | 5222 | 0.650 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 855 | 0.650 |
Why?
| | Societies, Medical | 3 | 2024 | 859 | 0.620 |
Why?
| | Infant | 29 | 2025 | 9820 | 0.610 |
Why?
| | General Practice | 1 | 2019 | 32 | 0.600 |
Why?
| | Adolescent | 39 | 2025 | 22116 | 0.590 |
Why?
| | Coronary Vessels | 2 | 2018 | 246 | 0.590 |
Why?
| | Primary Graft Dysfunction | 1 | 2019 | 34 | 0.580 |
Why?
| | Aortic Aneurysm, Thoracic | 2 | 2011 | 136 | 0.580 |
Why?
| | Myocardium | 9 | 2023 | 911 | 0.570 |
Why?
| | Biopsy | 9 | 2024 | 1073 | 0.560 |
Why?
| | Medication Adherence | 2 | 2019 | 510 | 0.550 |
Why?
| | Patient Selection | 3 | 2024 | 685 | 0.540 |
Why?
| | Humans | 90 | 2025 | 141284 | 0.530 |
Why?
| | Blood Group Incompatibility | 2 | 2024 | 17 | 0.530 |
Why?
| | ABO Blood-Group System | 2 | 2024 | 53 | 0.510 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2024 | 374 | 0.500 |
Why?
| | Risk Factors | 17 | 2024 | 10490 | 0.490 |
Why?
| | Male | 60 | 2025 | 70140 | 0.490 |
Why?
| | Echocardiography, Doppler | 2 | 2024 | 113 | 0.450 |
Why?
| | Female | 58 | 2025 | 75814 | 0.440 |
Why?
| | Ventricular Remodeling | 3 | 2024 | 258 | 0.430 |
Why?
| | Tissue and Organ Procurement | 5 | 2022 | 319 | 0.410 |
Why?
| | Cardiomyopathy, Hypertrophic | 4 | 2023 | 141 | 0.410 |
Why?
| | Tacrolimus | 2 | 2025 | 199 | 0.410 |
Why?
| | Coronary Artery Disease | 2 | 2024 | 716 | 0.400 |
Why?
| | Transplant Recipients | 2 | 2025 | 181 | 0.380 |
Why?
| | Hemodynamics | 4 | 2022 | 1106 | 0.380 |
Why?
| | Genetic Testing | 4 | 2024 | 462 | 0.380 |
Why?
| | Vascular Remodeling | 1 | 2014 | 196 | 0.370 |
Why?
| | Arrhythmias, Cardiac | 3 | 2013 | 345 | 0.370 |
Why?
| | Death, Sudden, Cardiac | 2 | 2012 | 193 | 0.370 |
Why?
| | Aneurysm | 1 | 2011 | 36 | 0.350 |
Why?
| | Treatment Outcome | 16 | 2025 | 11216 | 0.350 |
Why?
| | American Heart Association | 3 | 2019 | 299 | 0.350 |
Why?
| | Protein-Losing Enteropathies | 1 | 2011 | 10 | 0.340 |
Why?
| | Electrocardiography | 2 | 2014 | 626 | 0.340 |
Why?
| | Organ Transplantation | 2 | 2024 | 252 | 0.330 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2011 | 60 | 0.320 |
Why?
| | Aortic Valve | 2 | 2014 | 359 | 0.320 |
Why?
| | Defibrillators | 1 | 2010 | 23 | 0.320 |
Why?
| | Ventricular Fibrillation | 1 | 2010 | 62 | 0.310 |
Why?
| | Incidence | 7 | 2025 | 2809 | 0.290 |
Why?
| | Kidney Diseases | 2 | 2023 | 409 | 0.290 |
Why?
| | Ventricular Function, Left | 3 | 2024 | 513 | 0.290 |
Why?
| | Craniofacial Abnormalities | 1 | 2009 | 75 | 0.290 |
Why?
| | Mitral Valve | 1 | 2009 | 98 | 0.280 |
Why?
| | Infant, Newborn | 12 | 2024 | 6270 | 0.280 |
Why?
| | Tachycardia, Ventricular | 1 | 2010 | 177 | 0.280 |
Why?
| | Kidney Transplantation | 3 | 2023 | 680 | 0.280 |
Why?
| | Heart Ventricles | 4 | 2017 | 748 | 0.270 |
Why?
| | Predictive Value of Tests | 4 | 2024 | 2069 | 0.270 |
Why?
| | Severity of Illness Index | 6 | 2018 | 2904 | 0.260 |
Why?
| | Prognosis | 9 | 2024 | 4080 | 0.250 |
Why?
| | Allografts | 2 | 2024 | 148 | 0.250 |
Why?
| | Aorta, Thoracic | 1 | 2009 | 282 | 0.250 |
Why?
| | Glomerular Filtration Rate | 3 | 2024 | 755 | 0.250 |
Why?
| | Everolimus | 1 | 2025 | 110 | 0.230 |
Why?
| | Perioperative Care | 2 | 2017 | 228 | 0.220 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 118 | 0.220 |
Why?
| | Transplants | 2 | 2022 | 38 | 0.220 |
Why?
| | Peripheral Arterial Disease | 1 | 2011 | 491 | 0.220 |
Why?
| | Young Adult | 15 | 2024 | 13727 | 0.220 |
Why?
| | Palliative Care | 1 | 2012 | 820 | 0.220 |
Why?
| | Time Factors | 7 | 2024 | 6951 | 0.220 |
Why?
| | Vascular Resistance | 3 | 2014 | 364 | 0.220 |
Why?
| | Risk Assessment | 4 | 2023 | 3522 | 0.210 |
Why?
| | Adult | 24 | 2024 | 39319 | 0.210 |
Why?
| | Genetic Counseling | 1 | 2024 | 81 | 0.200 |
Why?
| | Databases, Factual | 1 | 2009 | 1449 | 0.200 |
Why?
| | Heart | 3 | 2023 | 616 | 0.200 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 175 | 0.200 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 411 | 0.200 |
Why?
| | Bacterial Infections | 1 | 2025 | 244 | 0.190 |
Why?
| | Contrast Media | 2 | 2023 | 476 | 0.180 |
Why?
| | Inheritance Patterns | 1 | 2022 | 44 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 1336 | 0.180 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2014 | 117 | 0.180 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 626 | 0.180 |
Why?
| | Magnetic Resonance Imaging, Cine | 3 | 2023 | 209 | 0.170 |
Why?
| | Echocardiography | 6 | 2018 | 647 | 0.170 |
Why?
| | Exome | 1 | 2022 | 235 | 0.170 |
Why?
| | Drug Monitoring | 2 | 2024 | 396 | 0.160 |
Why?
| | Prospective Studies | 7 | 2023 | 7805 | 0.160 |
Why?
| | Phenotype | 4 | 2022 | 3172 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 4 | 2022 | 2366 | 0.150 |
Why?
| | Noonan Syndrome | 1 | 2019 | 14 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 325 | 0.150 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 341 | 0.150 |
Why?
| | Pneumonia | 1 | 2025 | 634 | 0.150 |
Why?
| | United States | 14 | 2024 | 15298 | 0.140 |
Why?
| | Proportional Hazards Models | 7 | 2017 | 1268 | 0.140 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 1090 | 0.140 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 435 | 0.140 |
Why?
| | Hyperplasia | 1 | 2018 | 174 | 0.140 |
Why?
| | Global Health | 1 | 2021 | 384 | 0.140 |
Why?
| | Child Nutrition Disorders | 1 | 2018 | 20 | 0.140 |
Why?
| | Surgical Wound Dehiscence | 1 | 2017 | 22 | 0.140 |
Why?
| | Survival Analysis | 4 | 2021 | 1322 | 0.140 |
Why?
| | Cohort Studies | 6 | 2022 | 5809 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 910 | 0.140 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 599 | 0.130 |
Why?
| | Cognition Disorders | 1 | 2021 | 520 | 0.130 |
Why?
| | Death | 1 | 2017 | 124 | 0.130 |
Why?
| | Genotype | 1 | 2022 | 1854 | 0.130 |
Why?
| | Age Factors | 3 | 2024 | 3295 | 0.130 |
Why?
| | Myocardial Contraction | 2 | 2024 | 298 | 0.120 |
Why?
| | Executive Function | 1 | 2021 | 459 | 0.120 |
Why?
| | Extracorporeal Circulation | 1 | 2016 | 15 | 0.120 |
Why?
| | Sirolimus | 1 | 2017 | 276 | 0.120 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2015 | 4 | 0.120 |
Why?
| | Cardio-Renal Syndrome | 1 | 2015 | 13 | 0.120 |
Why?
| | Genes, Neurofibromatosis 1 | 1 | 2015 | 4 | 0.110 |
Why?
| | Pseudarthrosis | 1 | 2015 | 14 | 0.110 |
Why?
| | Cardiology | 1 | 2017 | 286 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 381 | 0.110 |
Why?
| | Neurofibromatosis 1 | 1 | 2015 | 55 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 321 | 0.110 |
Why?
| | Tachycardia | 1 | 2014 | 57 | 0.110 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2014 | 67 | 0.100 |
Why?
| | Cardiovascular Diseases | 3 | 2012 | 2091 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2019 | 802 | 0.100 |
Why?
| | Sequence Deletion | 1 | 2014 | 183 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 539 | 0.100 |
Why?
| | Pediatrics | 3 | 2016 | 1102 | 0.100 |
Why?
| | T-Box Domain Proteins | 1 | 2014 | 102 | 0.100 |
Why?
| | Tibia | 1 | 2015 | 182 | 0.100 |
Why?
| | Arterial Pressure | 1 | 2014 | 132 | 0.100 |
Why?
| | Age Distribution | 1 | 2014 | 396 | 0.100 |
Why?
| | Sex Distribution | 1 | 2014 | 381 | 0.100 |
Why?
| | Reoperation | 2 | 2021 | 599 | 0.100 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2012 | 11 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2022 | 2600 | 0.090 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 197 | 0.090 |
Why?
| | Middle Aged | 13 | 2017 | 34658 | 0.090 |
Why?
| | Immunoglobulins | 1 | 2012 | 162 | 0.090 |
Why?
| | Fibrosis | 3 | 2023 | 541 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1078 | 0.090 |
Why?
| | International Cooperation | 1 | 2012 | 195 | 0.090 |
Why?
| | Liver Diseases | 1 | 2014 | 301 | 0.090 |
Why?
| | Altitude Sickness | 1 | 2013 | 150 | 0.090 |
Why?
| | Glucaric Acid | 1 | 2011 | 4 | 0.090 |
Why?
| | Cardiotonic Agents | 1 | 2011 | 95 | 0.090 |
Why?
| | Tissue and Organ Harvesting | 1 | 2011 | 74 | 0.090 |
Why?
| | Hematinics | 1 | 2011 | 21 | 0.090 |
Why?
| | Capillaries | 1 | 2012 | 121 | 0.090 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2011 | 120 | 0.080 |
Why?
| | Stroke Volume | 1 | 2014 | 598 | 0.080 |
Why?
| | Treatment Failure | 1 | 2012 | 355 | 0.080 |
Why?
| | Ferric Compounds | 1 | 2011 | 55 | 0.080 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2010 | 34 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2018 | 604 | 0.080 |
Why?
| | Diverticulum | 1 | 2010 | 12 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 674 | 0.080 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2010 | 39 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2017 | 948 | 0.080 |
Why?
| | Propanolamines | 1 | 2010 | 39 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 56 | 0.080 |
Why?
| | Kidney Function Tests | 2 | 2024 | 159 | 0.080 |
Why?
| | Disease Management | 1 | 2014 | 634 | 0.080 |
Why?
| | Recovery of Function | 1 | 2014 | 684 | 0.080 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 98 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 248 | 0.080 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2009 | 29 | 0.080 |
Why?
| | Mutation | 3 | 2019 | 4006 | 0.080 |
Why?
| | Heart-Lung Transplantation | 2 | 2024 | 13 | 0.080 |
Why?
| | Resource Allocation | 1 | 2009 | 51 | 0.070 |
Why?
| | Dopamine | 1 | 2011 | 304 | 0.070 |
Why?
| | Syndrome | 1 | 2009 | 376 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2010 | 373 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 2014 | 1115 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5653 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1505 | 0.070 |
Why?
| | Risk | 1 | 2010 | 903 | 0.070 |
Why?
| | Defibrillators, Implantable | 1 | 2010 | 318 | 0.070 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2009 | 188 | 0.070 |
Why?
| | Connexin 43 | 1 | 2007 | 35 | 0.070 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 1 | 2007 | 57 | 0.060 |
Why?
| | Wound Healing | 1 | 2009 | 349 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2020 | 561 | 0.060 |
Why?
| | Morbidity | 2 | 2021 | 320 | 0.060 |
Why?
| | Health Policy | 1 | 2009 | 385 | 0.060 |
Why?
| | Cadherins | 1 | 2007 | 200 | 0.060 |
Why?
| | Patient Compliance | 1 | 2010 | 607 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2025 | 2047 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5948 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2025 | 60 | 0.060 |
Why?
| | Biomarkers | 4 | 2023 | 4180 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2765 | 0.060 |
Why?
| | Canada | 2 | 2017 | 420 | 0.060 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 197 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 324 | 0.050 |
Why?
| | Gadolinium | 1 | 2023 | 85 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 1043 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2022 | 70 | 0.050 |
Why?
| | Myocytes, Cardiac | 1 | 2007 | 530 | 0.050 |
Why?
| | Cause of Death | 2 | 2015 | 449 | 0.050 |
Why?
| | Living Donors | 1 | 2023 | 269 | 0.040 |
Why?
| | Quality of Life | 2 | 2023 | 3024 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2024 | 843 | 0.040 |
Why?
| | Aged | 4 | 2017 | 24836 | 0.040 |
Why?
| | Utah | 2 | 2012 | 74 | 0.040 |
Why?
| | Age of Onset | 1 | 2022 | 536 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2022 | 672 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2019 | 44 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2019 | 22 | 0.040 |
Why?
| | Logistic Models | 1 | 2024 | 2098 | 0.040 |
Why?
| | Genes, ras | 1 | 2019 | 94 | 0.040 |
Why?
| | Immunity, Cellular | 2 | 2012 | 266 | 0.040 |
Why?
| | ras Proteins | 1 | 2019 | 145 | 0.040 |
Why?
| | Postoperative Period | 1 | 2019 | 359 | 0.030 |
Why?
| | Prevalence | 2 | 2015 | 2795 | 0.030 |
Why?
| | Machine Learning | 1 | 2023 | 555 | 0.030 |
Why?
| | Adenoidectomy | 1 | 2017 | 73 | 0.030 |
Why?
| | Brazil | 1 | 2017 | 168 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2929 | 0.030 |
Why?
| | Sample Size | 1 | 2017 | 126 | 0.030 |
Why?
| | Genetic Variation | 1 | 2022 | 993 | 0.030 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 128 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 321 | 0.030 |
Why?
| | Tonsillectomy | 1 | 2017 | 97 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 680 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1482 | 0.030 |
Why?
| | Gadolinium DTPA | 1 | 2016 | 71 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 771 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 282 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1456 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 231 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 1312 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1761 | 0.030 |
Why?
| | Lower Extremity Deformities, Congenital | 1 | 2014 | 3 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1866 | 0.030 |
Why?
| | Upper Extremity Deformities, Congenital | 1 | 2014 | 6 | 0.030 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.030 |
Why?
| | Comparative Genomic Hybridization | 1 | 2014 | 29 | 0.030 |
Why?
| | Breast Diseases | 1 | 2014 | 22 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 61 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1671 | 0.030 |
Why?
| | Ulna | 1 | 2014 | 36 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2022 | 3577 | 0.030 |
Why?
| | Aortic Valve Insufficiency | 1 | 2014 | 44 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 594 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1005 | 0.030 |
Why?
| | Drug Therapy | 1 | 2014 | 81 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1655 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1546 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 396 | 0.030 |
Why?
| | Preoperative Period | 1 | 2014 | 143 | 0.030 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2014 | 60 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 845 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2014 | 373 | 0.020 |
Why?
| | Population Dynamics | 1 | 2013 | 153 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 298 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2014 | 316 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2012 | 88 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 2017 | 587 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2012 | 134 | 0.020 |
Why?
| | Brain Death | 1 | 2011 | 51 | 0.020 |
Why?
| | Complement C4b | 1 | 2010 | 9 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 874 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1610 | 0.020 |
Why?
| | Necrosis | 1 | 2011 | 245 | 0.020 |
Why?
| | Complement C3d | 1 | 2010 | 67 | 0.020 |
Why?
| | Diastole | 1 | 2010 | 141 | 0.020 |
Why?
| | Systole | 1 | 2010 | 175 | 0.020 |
Why?
| | Ultrasonography | 1 | 2014 | 765 | 0.020 |
Why?
| | Fibrin | 1 | 2010 | 90 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1807 | 0.020 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 286 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 222 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1178 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 3345 | 0.020 |
Why?
| | Isoantibodies | 1 | 2008 | 56 | 0.020 |
Why?
| | Ischemia | 1 | 2011 | 413 | 0.020 |
Why?
| | Oxygen | 1 | 2013 | 986 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2012 | 768 | 0.020 |
Why?
| | Gap Junctions | 1 | 2007 | 63 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2007 | 154 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2010 | 696 | 0.020 |
Why?
| | Regression Analysis | 1 | 2008 | 1013 | 0.020 |
Why?
| | Dogs | 1 | 2007 | 423 | 0.010 |
Why?
| | Disease Progression | 1 | 2013 | 2808 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1220 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 815 | 0.010 |
Why?
| | Stroke | 1 | 2012 | 1199 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3734 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2007 | 4414 | 0.010 |
Why?
| | Animals | 1 | 2007 | 37328 | 0.000 |
Why?
|
|
Everitt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|